POL:08:LP:003:03:NIBT PAGE : 1 of 5. Document Title: NIBTS POLICY FOR RETURN AND RE-ISSUE OF BLOOD AND BLOOD COMPONENTS

Similar documents
POL:02:UP:001:07:NIBT PAGE 1 of 6 ISSUE DATE: 12 DECEMBER 2014 EFFECTIVE DATE: 9 JANUARY 2015

POL:00:QP:001:03:NIBT PAGE 1 of 8. Document Details Document Number: POL:00:QP:001:03:NIBT No. of Appendices: 1 Supersedes Number: 00:02:QP:001:NIBT

SOP:14:QA:110:01:NIBT PAGE 1 of 8

SOP:07:QA:070:08:NIBT PAGE 1 of 26

Right Patient Right Blood Monitoring Compliance Reference Number:

Blood Transfusion Policy. Version Number: 6.1 Controlled Document Sponsor: Controlled Document Lead: On: December 2014.

ACTIONS/PSOP/001 Version 1.0 Page 2 of 6

HAEMOVIGILANCE POLICY

Sample. A guide to development of a hospital blood transfusion Policy at the hospital level. Effective from April Hospital Transfusion Committee

Clinical. Medication Errors and Medicine Defect Reporting SOP. Document Control Summary. Contents

Electronic Blood Tracking System

Quality Management Training for Blood Transfusion Services

Standard Operating Procedure (SOP) Research and Development Office

Guidance on Standard Operating Procedures for the Safer Management of Controlled Drugs in Registered Facilities. July 2011

Title Controlled Storage of Blood and Blood Products Standard Operating Procedure

AATB s Report: Adverse Reporting Systems & Requirements

UK TRANSFUSION LABORATORY COLLABORATIVE

List of Policies and Standard Operational Procedures (SOPs) for cell collection, processing and transplantation programmes

Clinical Interdepartmental Policy and Procedure

Use of Intravenous devices for administration of fluid therapy in Neonates

STANDARD OPERATING PROCEDURE

HAEMOVIGILANCE. Ms. Emma O Riordan Haemovigilance, CNM2 (Acting) Ms. Bríd Doyle, MSc. FAMLS. Haemovigilance Co-ordinator, (Acting)

Private Practice by Medical Staff - Code of Conduct

Linen Services and Patients Personal Clothing

REPORT OF BLOOD SAFETY REVIEW

Job Description. Senior Biomedical Scientists & Head and Deputy Head of Department. Head of Department (Biochemistry) & Blood Sciences Manager

Guidance on the Delivery of Medicines Dispensed on Foot of a Prescription from a Retail Pharmacy Business

Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust

Medicines Management Policy

Laboratory Request Form Completion and Specimen Labelling Reference Number:

Guidelines on the Keeping of Records in Respect of Medicinal Products when Conducting a Retail Pharmacy Business

Competency Framework for the Administration of all Blood Products

Study Monitoring Plan Template

Standard Operating Procedure Research Governance

Policy on adherence to Clinical Nursing / Midwifery Procedures

Guidance for MRC units on HTA licence applications for storage of human samples for research purposes

Royal Wolverhampton Hospitals NHS Trust. Job Description Haematology

STANDARD OPERATING PROCEDURE SOP 715. Principles of Clinical Research Laboratory Practice

Standard Operating Procedure (SOP) Research and Development Office

Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research

Procedure to Allow Nursing Staff to Dispense Leave and Discharge Medication

CONSENT POLICY Page 1 of 8 Reviewed: March 2017

Administration of blood components. Denise Watson Patient Blood Management Practitioner 11th January, 2016

ENDOSCOPY MICROBIOLOGY ALERTS PROCEDURE STANDARD OPERATING PROCEDURE

Consent for Blood Transfusion

A Guide To Safe Blood Transfusion Practice

Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs

Standard Operating Procedure (SOP) for Reporting Urgent Safety Measures in Clinical Research

MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC

Trial Management: Trial Master Files and Investigator Site Files

The Transfusion Medicine diplomate will respect the rights of the individual and family and must

The document has been issued to:- Name Position Department Date

Qualifications Support Pack 03. Making Claims & Results

Hazard Analysis & Critical Control Points

Marie-Claire Rickard, Governance and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager

STANDARD OPERATING PROCEDURE SOP 325

Response to Safety Events Just Culture HR Policy 5.24 Page 1 of 10

Document Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator

Irradiated blood products - Pathway for requesting To provide healthcare professionals with clear guidance on the use of irradiated blood products.

Human Samples in Research

Regulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center

Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026

Research Staff Training

MHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

General Chiropractic Council. Guidance consultation: Consent

DIAGNOSTIC CLINICAL TESTS AND SCREENING PROCEDURES MANAGEMENT POLICY

Better Blood Transfusion & anti-d Immunoglobulin

Document Title: Investigator Site File. Document Number: 019

Pan Dorset Procedure for the Management of the Closure of a Care Home Supporting people in Dorset to lead healthier lives

Post-accreditation monitoring report: Association of Business Executives (ABE) March 2008 QCA/08/3699

The Update June 2016

Guidance on the Supply by Pharmacists in Retail Pharmacy Businesses of Medicines to Patients in Residential Care Settings/Nursing Homes

Unofficial copy not valid

NHS Blood and Transplant (NHSBT) Board 30 November Clinical Governance Report 01 August 30 th September 2017

Blood / Blood Products Transfusion A Liquid Transplant

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

Details: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure

Advanced Oral & Maxillofacial Surgery, Ltd. NOTICE OF PRIVACY PRACTICES

Version Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13

Decontamination of Medical and Laboratory Equipment Prior to Maintenance or Transportation

Registration of Health and Social Care Professions

The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services

Inspection decision making framework

STANDARD OPERATING PROCEDURE

ASBESTOS MANAGEMENT POLICY

New v1.0 Date: Cathy Riley - Director of Pharmacy Policy and Procedures Committee Policy and Procedures Committee

2.0 Base Shrewsbury and Telford Hospital NHS Trust

Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES

Laboratory Errors n=455 and MHRA 5 Serious Adverse Events n=765

Standard Operating Procedure (SOP)

Setting up a Clinical Trial

Section 18 Absent without Leave Photographing Patients

Quality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D

STANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager

Hepatitis B Immunisation procedure SOP

Document Title: Document Number:

National Patient Safety Agency Root Cause Analysis (RCA) Investigation

Management of Reported Medication Errors Policy

Procedure for the Management of a Patient being Absent without Leave (Absconding) from a Hospital Environment

Transcription:

POL:08:LP:003:03:NIBT PAGE : 1 of 5 Northern Ireland Blood Transfusion Service POLICY DOCUMENT Document Details Document Number: POL:08:LP:003:03:NIBT Supersedes Number: 08:02:LP:003:NIBT No. of Appendices: NONE Document Title: NIBTS POLICY FOR RETURN AND RE-ISSUE OF BLOOD AND BLOOD COMPONENTS ISSUE DATE: 26 NOVEMBER 2014 EFFECTIVE DATE: 24 DECEMBER 2014 Document Authorisation: Written By: Pauline Gowdy, Hospital Services Manager Signature: Date: Authorised By: Catherine Ferguson, Laboratory Manager Signature: Date: Authorised By: Mr Mervyn Barkley, Chief Executive Signature: Date: CROSS REFERENCES This Policy refers to the following documents: Doc Type Doc. No. Title FORM DD:046 Recall Notification And Component Fate Form FORM DD:062 NIBTS Blood component or Blood product returns Form SOP QA:002 Blood Component Recall Procedure SOP BI:044 Return of in date components which may be re-issued FORM DD:1142 NIBTS component returns for re-issue form FORM DD:1040 Recall record form

POL:08:LP:003:03:NIBT PAGE : 2 of 5 Key Change from Previous Revision: Inclusion of SOP:BI:044 and FORM:DD:1142 when returning blood for re-issue. Amend Equality Statement 1 STATEMENT It is a fundamental requirement of the NIBTS Quality Management System that all components which are considered to pose a risk to patients are withdrawn from use. A recall may be initiated for many reasons, including the following: Donation(s) found to have been collected from donor(s) who did not meet standard acceptance criteria, e.g. following post donation notifications/potentially infective donation Problems identified with donation testing. Problems identified with quality of raw materials e.g. blood bag faults/faulty labels. Adverse post transfusion reactions requiring the recall of other implicated components. Hospital no longer requires components or notifies NIBTS that the incorrect product was received. Note: Recall in this instance can only be initiated after approval from the Regulatory Affairs and Compliance Manager/Deputy during normal working hours or the NIBTS Consultant On Call outside normal working hours. Issued component is found to be suitable HLA match for a patient in a different hospital. For an incident in which the quality or safety of products may be compromised. A recall may be initiated from an internal or external source. It is not NIBTS policy to routinely accept returns of issued blood and re-issue of blood / blood components after recall must comply with strict conditions, to ensure the safety of the patient. This policy has been developed to outline the circumstances, which will permit staff to accept and reissue returned blood and blood components.

POL:08:LP:003:03:NIBT PAGE : 3 of 5 2 OVERVIEW The NIBTS Agency does not routinely accept returns of issued blood components from hospitals. However, returns can infrequently be requested by NIBTS for a variety of reasons. Some of these reasons may include: a failure in the quality of the product, new donor information coming to light, the return of components for the subsequent reissue to a different location e.g. specific phenotyped blood or HLA matched components. This policy attempts to give guidance to staff for the re-issue of blood components after recall. 3 RESPONSIBILITY Regulatory Affairs and Compliance Manager or Approved Deputy is responsible for approving the re-issue of blood / blood components during normal working hours. The Consultant on call is responsible for approving the re-issue of blood / blood components outside normal working hours. Hospital Services staff are responsible for recall / re-issue during normal working hours. On-Call staff are responsible for recall / re-issue outside normal working hours. 4 POLICY 4.1 RECALL Recall is instigated in accordance with NIBTS recall procedure SOP:QA:002 and recorded using FORM:DD:1040. Please also refer to SOP:BI:044 Return of in date components which may be re-issued. Completed documentation must be received from the recall location before NIBTS can consider reissue of blood products or components. The return of components to stock with the intention of re-issue must be approved by the Regulatory Affairs & Compliance Manager or Deputy during normal working hours or the Medical Consultant out of Hours. 4.2 RETURNS All blood components and products must be returned to Pulse Donor Management System whether or not they are for re-issue. This is to ensure a complete audit trail is maintained. Product which has been recalled for reasons of inferior quality must not be re-issued to another clinical location. 4.3 RECALL OF PRODUCTS SUITABLE FOR REISSUE Products/components may be recalled for re-issue for a variety of reasons. Some are detailed below but this list is not exhaustive.

POL:08:LP:003:03:NIBT PAGE : 4 of 5 4.3.1 Issued components found subsequently to be a suitable HLA match for a specific patient and no other suitable units are available at NIBTS 4.3.2 Phenotyped red cells when insufficient are available at NIBTS and request for transfusion is urgent. 4.3.3 Low stock at NIBTS of particular blood components or products. 4.3.4 Inadvertent over ordering by hospitals in response to an emergency. 4.3.5 Error in issue by NIBTS where wrong product is dispatched. 4.4 REISSUE Products may only be re-issued if the following criteria are established. 4.4.1 Recall form FORM:DD:046 and storage FORM:DD:062 are returned from hospital. 4.4.2 Returning hospitals must be MHRA compliant. 4.4.3 FORM:DD:062 and FORM:DD:1142 must be completed with all required information. 4.4.4 The blood or components have not been outside temperature monitored storage. 4.4.5 The blood components or products must not have been issued from hospital blood banks to wards or theatres. 4.4.6 Any further situations not documented here but which the Hospital Services Manager and Regulatory Affairs and Compliance Manager have considered and deemed not to be a risk. 5 EQUALITY SCREENING OUTCOME This policy has been drawn up and reviewed in light of the statutory obligations contained within Section 75 of the Northern Ireland Act (1998). In line with this statutory duty of equality this policy has been screened against particular criteria. If at any stage of the life of the policy there are any issues within the policy which are perceived by any party as creating adverse impacts on any of the groups under Section 75 that party should bring these to the attention of the Head of HR & Corporate Services. The Northern Ireland Blood Transfusion Service is committed to the promotion of equality of opportunity for staff, donors and service users. We strive to ensure that everyone is treated fairly and that their rights are respected at all times. We believe that it is important that our policy is understood by all those whose literacy is limited, those who do not speak English as a first language or those who face communication barriers because of a disability. On request it may be possible to make this policy

POL:08:LP:003:03:NIBT PAGE : 5 of 5 available in alternative formats such as large print, Braille, disk, audio file, audio cassette, Easy Read or in minority languages to meet the needs of those not fluent in English. 6 TRAINING REQUIREMENTS The following staff must read and understand the policy RAC Manager or approved deputy Consultant on call Hospital Services Manager / Deputy All Hospital Services staff All On Call staff All rotational laboratory staff